Sun Pharma Q1FY26: Revenue up 10.1% YoY, Adjusted Net Profit rises 5.7%
The strong financial performance, new product launches, and expansion in key markets suggest a significant positive impact on the company's growth and shareholder value.
The announcement highlights positive financial results, including increased sales and profits, along with the launch of new products and strategic progress in various markets.
* Sun Pharma's consolidated Q1FY26 results show strong growth. * Gross sales reached ₹1,378.61 crore (₹13,786.1 million), a 10.1% increase year-over-year. * India formulation sales grew by 13.9% to ₹472.11 crore (₹4,721.1 million), contributing 34.2% to total consolidated sales. * US formulation sales amounted to US$ 473 million, a 1.4% increase. * Global Innovative Medicines sales increased by 16.9% to US$ 311 million, accounting for 19.3% of Q1FY26 sales. * Emerging Markets formulation sales grew by 5.1% to US$ 298 million. * Rest of World formulation sales increased by 15.5% to US$ 219 million. * R&D investments were ₹90.29 crore (₹902.9 million), or 6.5% of sales, compared to ₹79.40 crore (₹794 million) in Q1FY25. * EBITDA rose by 19.2% to ₹430.17 crore (₹4,301.7 million), with an EBITDA margin of 31.1%. * Profit before exceptional items and tax increased by 16.6% to ₹399.08 crore (₹3,990.8 million). * Adjusted net profit (excluding exceptional items) for Q1FY26 was ₹299.61 crore (₹2,996.1 million), up 5.7%. * Reported net profit for Q1FY26 was ₹227.86 crore (₹2,278.6 million), compared to ₹283.56 crore (₹2,835.6 million) during Q1FY25. * The company launched 5 new products in the Indian market during the quarter. * External API sales were ₹54.04 crore (₹540.4 million), up by 9.3%. * Dilip Shanghvi, Chairman and Managing Director, noted the strong performance and steady progress across markets, highlighting the U.S. launch of LEQSE LVI as an important step forward in dermatology.
What to do with a filing like this
Sun Pharmaceutical Industries Limited filed this with the NSE as a statutory disclosure, categorised under results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sun Pharmaceutical Industries Limited. Read the original for the full detail.